MICA is not a direct humoral allogeneic target in steroid-refractory chronic graft-versus-host disease

被引：0
|
作者：
Whittle, R. [1 ]
Goodwin, J. [2 ]
Smillie, D. [2 ]
Harmer, A. [2 ]
Taylor, P. [1 ]
机构：
[1] Rotherham Gen Hosp, Dept Haematol, Rotherham, S Yorkshire, England
[2] NHS Blood & Transplant, H&I Dept, Sheffield, S Yorkshire, England
来源：
INTERNATIONAL JOURNAL OF IMMUNOGENETICS | 2010年 / 37卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
引用
收藏
页码：430 / 430
页数：1
相关论文
共 50 条
  • [1] Rituximab for steroid-refractory chronic graft-versus-host disease
    Cutler, Corey
    Miklos, David
    Kim, Haesook T.
    Treister, Nathaniel
    Woo, Sook-Bin
    Bienfang, Don
    Klickstein, Lloyd B.
    Levin, Jesse
    Miller, Katherine
    Reynolds, Carol
    Macdonell, Rebecca
    Pasek, Mildred
    Lee, Stephanie J.
    Ho, Vincent
    Soiffer, Robert
    Antin, Joseph H.
    Ritz, Jerome
    Alyea, Edwin
    BLOOD, 2006, 108 (02) : 756 - 762
  • [2] Pentostatin in steroid-refractory chronic graft-versus-host disease
    Bolanos-Meade, J
    Jacobsohn, D
    Anders, V
    Higman, M
    Chen, A
    Phelps, M
    Vogelsang, GB
    BLOOD, 2005, 106 (11) : 513A - 514A
  • [3] Pulse Cyclophosphamide for Steroid-Refractory Chronic Graft-Versus-Host Disease
    Chao, Nelson J.
    Foster, Yevgeniya Gora
    Rowe, Krista
    Shah, Ankoor
    Cardones, Adela Rambi
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S393 - S395
  • [4] Hedgehog blockade in steroid-refractory sclerotic chronic graft-versus-host disease
    Radojcic, Vedran
    Pletneva, Maria
    Lee, Catherine J.
    Ivcevic, Sanja
    Sarantopoulos, Stefanie
    Couriel, Daniel
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 195 (02) : E120 - E122
  • [5] Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease
    Okamoto, M
    Okano, A
    Akamatsu, S
    Ashihara, E
    Inaba, T
    Takenaka, H
    Katoh, N
    Kishimoto, S
    Shimazaki, C
    LEUKEMIA, 2006, 20 (01) : 172 - 173
  • [6] Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease
    M Okamoto
    A Okano
    S Akamatsu
    E Ashihara
    T Inaba
    H Takenaka
    N Katoh
    S Kishimoto
    C Shimazaki
    Leukemia, 2006, 20 : 172 - 173
  • [7] Brentixumab vedotin for the treatment of steroid-refractory chronic graft-versus-host disease
    DeFilipp, Zachariah
    Li, Shuli
    Kempner, Maria
    Brown, Jami
    Del Rio, Candice
    Valles, Betsy
    Ballen, Karen
    Dey, Bimalangshu
    El-Jawahri, Areej
    McAfee, Steven
    Spitzer, Thomas
    Chen, Yi-Bin
    BONE MARROW TRANSPLANTATION, 2018, 53 : 398 - 398
  • [8] Ruxolitinib treatment for steroid-refractory graft-versus-host disease
    Park, Han-Seung
    Lee, Je-Hwan
    Lee, Jung-Hee
    Choi, Eun-Ji
    Seol, Miee
    Lee, Young-Shin
    Kang, Young-Ah
    Jeon, Mijin
    Lee, Kyoo-Hyung
    BONE MARROW TRANSPLANTATION, 2019, 54 : 323 - 324
  • [9] Ruxolitinib for steroid-refractory acute graft-versus-host disease
    Toama, Wael
    Fiala, Mark
    Pusic, Iskra
    Westervelt, Peter
    Dipersio, John F.
    Schroeder, Mark
    TRANSPLANT INTERNATIONAL, 2020, 33 (02) : 244 - 246
  • [10] Pentostatin in steroid-refractory acute graft-versus-host disease
    Bolaños-Meade, J
    Jacobsohn, DA
    Margolis, J
    Ogden, A
    Wientjes, MG
    Byrd, JC
    Lucas, DM
    Anders, V
    Phelps, M
    Grever, MR
    Vogelsang, GB
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) : 2661 - 2668
12345